Dexcom, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter earnings report; the supplied filing text does not provide a clear standalone Q4 financial summary. Dexcom develops and sells continuous glucose monitoring (CGM) systems, principally the G6, and is pursuing regulatory approval of its next-generation G7.
Financial performance
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $2,448.5 million | $1,926.7 million | +27% |
| Gross profit / margin | $1,680.5 million / 68.6% | $1,280.1 million / 66.4% | +31%; margin +2.2 points |
| Operating income / margin | $265.8 million / 10.9% | $299.5 million / 15.5% | -11% |
| Net income / diluted EPS | $154.7 million / $1.55 | $493.6 million / $5.06 | Net income -69% |
| Cash from operations | $442.5 million | $475.6 million | -7% |
| Capital expenditures | $389.2 million | $199.0 million | Nearly doubled |
Revenue growth was primarily driven by higher disposable-sensor sales and customer growth, partly offset by channel mix and pricing. Disposable sensors and other revenue were 84% of total revenue, versus 81% in 2020. Gross-margin improvement reflected product-design savings, manufacturing efficiencies and scale. Operating expenses rose 44% to $1,414.7 million, including higher R&D and marketing spending and an $87.1 million Verily collaboration milestone charge recorded in Q4.
Net income declined largely because 2020 included a $268.6 million income-tax benefit, primarily from releasing a valuation allowance on deferred tax assets. FY2021 income-tax expense was $19.2 million. Operating income also fell as expense growth exceeded gross-profit growth.
Liquidity, debt and other key metrics
- Cash, cash equivalents and short-term marketable securities totaled $2.73 billion at year-end; approximately 95% was located in the United States.
- Working-capital ratio was 5.11 and quick ratio was 4.50 at December 31, 2021.
- Convertible notes had $1,999.8 million aggregate principal outstanding, with stated maturities in December 2023 and November 2025; their balance-sheet carrying amount was $1,702.7 million. Interest expense was $100.3 million.
- The amended five-year revolving credit facility provides $200 million, with no borrowings and $192.7 million available after letters of credit at year-end. Dexcom reported compliance with its covenants.
- Distributor sales were 83% of revenue, up from 75%; direct sales were 17%. Four distributors each generated at least 10% of FY2021 revenue.
- Revenue outside the United States was $599.1 million, or 24% of total, compared with 22% in 2020.
Material changes, outlook and risks
- Management expects positive operating cash inflows to continue and believes available cash and investments, operating cash flow and the credit facility will cover anticipated liquidity needs for at least the next 12 months. No specific FY2022 revenue or earnings guidance is provided in the supplied text.
- Dexcom expects significant investment in Malaysia manufacturing build-out and capacity expansion in Mesa, Arizona. It identifies G7 development, regulatory approval and commercialization, manufacturing scale-up, reimbursement, and competition as important business drivers.
- COVID-19 caused moderate operating disruptions, including supply-chain constraints affecting next-generation CGM development. Management said the future financial impact remained uncertain.
- Key risks include payer pricing and coverage pressure, manufacturing capacity and single-source suppliers, product quality and regulatory approvals, competition, cybersecurity and privacy, and international operations.
- Dexcom and Abbott entities brought patent-related actions against each other in multiple jurisdictions during 2021. The company said it intended to pursue its claims and defenses; it did not identify other pending proceedings it believed could materially affect results.
- The $87.1 million Verily charge followed management’s determination that a regulatory-approval milestone had become probable. Additional sales-based milestones may be payable in shares or cash; Dexcom stated its intention to pay in shares.
Investor verification priorities
- Confirm the drivers of revenue growth and whether distributor concentration and the shift toward distributor sales affect pricing, margins, collections or customer support.
- Track G7 regulatory and launch timing, manufacturing readiness, and the eventual accounting and dilution effects of Verily milestone payments.
- Assess operating cash flow alongside higher inventory, capital spending and manufacturing commitments; FY2021 inventory rose to $357.3 million from $234.7 million.
- Review convertible-note conversion, repayment and dilution exposure, including the 2023 and 2025 maturities and related credit-facility restrictions.
- Monitor Abbott patent litigation, reimbursement policy changes, and supply-chain or quality issues that could affect product availability and sales.